The estimated Net Worth of Robert Alexander is at least $18.6 Milion dollars as of 2 June 2021. Robert Alexander owns over 63,597 units of Allakos Inc stock worth over $202,072 and over the last 6 years he sold ALLK stock worth over $5,849,016. In addition, he makes $12,559,300 as Chief Executive Officer a Director at Allakos Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Alexander ALLK stock SEC Form 4 insiders trading
Robert has made over 4 trades of the Allakos Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 63,597 units of ALLK stock worth $5,849,016 on 2 June 2021.
The largest trade he's ever made was selling 63,597 units of Allakos Inc stock on 2 June 2021 worth over $5,849,016. On average, Robert trades about 6,496 units every 6 days since 2018. As of 2 June 2021 he still owns at least 331,266 units of Allakos Inc stock.
You can see the complete history of Robert Alexander stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Alexander biography
Dr. Robert D. Alexander Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Alexander previously served as our President from November 2017 through August 2019 and as a member of our board of directors from December 2012 until June 2013. From December 2013 to April 2017, Dr. Alexander served as Chief Executive Officer of ZS Pharma (acquired by AstraZeneca in December 2015), where he also served as a member of the board of directors, including as Chairman from March 2013 to March 2014. From November 2005 to March 2013, Dr. Alexander served as a Director at Alta Partners, a venture capital firm in life sciences. In addition, he acted as Executive Chairman and interim Chief Executive Officer of SARcode Biosciences (acquired by Shire plc in April 2013), a biopharmaceutical company. During his time at Alta, he led investments in SARcode Biosciences, Lumena Pharmaceuticals, ZS Pharma and Allakos. Previously, Dr. Alexander was a Principal in MPM Capital’s BioEquities fund where he sourced opportunities and led due diligence efforts for both public and private investments. Dr. Alexander also previously worked in the Business Development group at Genentech (now a member of the Roche Group), a biotechnology company, where he was responsible for sourcing and screening product opportunities based on scientific merit and strategic fit, leading diligence teams and negotiating terms and definitive agreements. He is currently a director at Allena Pharmaceuticals. Dr. Alexander joined Genentech after completing his post-doctoral fellowship at Stanford University in the Pathology department. He also holds a Ph.D. with a focus in immunology from the University of North Carolina and a B.A. in zoology from Miami University of Ohio.
What is the salary of Robert Alexander?
As the Chief Executive Officer a Director of Allakos Inc, the total compensation of Robert Alexander at Allakos Inc is $12,559,300. There are no executives at Allakos Inc getting paid more.
How old is Robert Alexander?
Robert Alexander is 50, he's been the Chief Executive Officer a Director of Allakos Inc since 2019. There are 8 older and 1 younger executives at Allakos Inc. The oldest executive at Allakos Inc is Steven James, 62, who is the Independent Director.
What's Robert Alexander's mailing address?
Robert's mailing address filed with the SEC is 825 INDUSTRIAL ROAD, SUITE 500, , SAN CARLOS, CA, 94070.
Insiders trading at Allakos Inc
Over the last 6 years, insiders at Allakos Inc have traded over $246,100,922 worth of Allakos Inc stock and bought 5,181,222 units worth $35,384,176 . The most active insiders traders include Paul Edward Walker, Group, Llc Green Jeremy Red... a Daniel Janney. On average, Allakos Inc executives and independent directors trade stock every 43 days with the average trade being worth of $114,372. The most recent stock trade was executed by Harlan Baird Radford on 28 June 2024, trading 87,064 units of ALLK stock currently worth $87,935.
What does Allakos Inc do?
allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.
What does Allakos Inc's logo look like?
Complete history of Robert Alexander stock trades at Allena Pharmaceuticals Inc a Allakos Inc
Allakos Inc executives and stock owners
Allakos Inc executives and other stock owners filed with the SEC include:
-
Robert Alexander,
Chief Executive Officer, Director -
Adam Tomasi,
President, Chief Operating Officer -
Henrik Rasmussen,
Chief Medical Officer -
Leo Redmond,
Chief Financial Officer -
Mark Asbury,
Chief Legal Officer and General Counsel -
Dr. Robert Alexander Ph.D.,
CEO & Director -
Dr. Adam L. Tomasi Ph.D.,
Pres & COO -
Dr. Henrik Sandvad Rasmussen,
Strategic Advisor -
Mark Asbury,
Chief Legal Officer & Gen. Counsel -
Daniel Janney,
Independent Chair of the Board -
Robert Andreatta,
Independent Director -
John McKearn,
Independent Director -
Paul Walker,
Independent Director -
Steven James,
Independent Director -
Dr. Craig Paterson M.D.,
Chief Medical Officer -
Alan Chang,
Director of Medical Affairs & Data Analytics -
Tim Varacek,
Chief Commercial Officer -
Dr. Sally D. Bolmer,
Sr. VP of Regulatory Affairs & Drug Devel. -
Dr. Ruby Casareno Ph.D.,
Sr. VP of Technical Operations -
Baird Radford III,
Chief Financial Officer -
Group, Llc Green Jeremy Red...,
-
Venture Fund Iii, L.P.River...,
-
Partners Viii, L.P.Alta Par...,
-
Neil Murray Hamilton Graham,
-
Amy L Ladd,
-
Dolca Thomas,
-
Partners Next Gen Fund I Ma...,
-
Peter A Hudson,
-
Robert J More,
-
Guy P Nohra,
10% owner -
Natalie C. Holles,
Director -
Partners Next Gen Fund I Ma...,
-
Margaret Nell Fitzgerald,
General Counsel and Secretary -
Craig A. Paterson,
Chief Medical Officer -
Everett Rand Sutherland,
Director -
Partners Management Viii, L...,
-
Chin Hyok Lee,
Chief Medical Officer -
Harlan Baird Radford,
Chief Financial Officer